Trials / Completed
CompletedNCT03012841
STOP Persistent AF
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Medtronic Cardiac Ablation Solutions · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate safety and effectiveness of the Arctic Front Advance™ and Freezor MAX® Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (AF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Arctic Front Advance Cardiac CryoAblation Catheter | Cryoablation |
Timeline
- Start date
- 2017-03-02
- Primary completion
- 2019-08-13
- Completion
- 2019-08-13
- First posted
- 2017-01-06
- Last updated
- 2025-02-13
- Results posted
- 2020-08-21
Locations
25 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03012841. Inclusion in this directory is not an endorsement.